Over the past 12 months, 4 insiders at Apogee Therapeutics, Inc. filed 79 open-market SEC Form 4 transactions on APGE: 0 purchases worth $0 and 79 sales worth $173.0M. Insiders have been net sellers over this period. The most recent filing was on Jul 8, 26.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| Jul 8, 26 | Michael Thomas HendersonChief Executive Officer | SELL | 20.0K | $133.63 | $2.7M |
| Jul 1, 26 | Carl DambkowskiChief Medical Officer | SELL | 5.5K | $132.74 | $730K |
| Jun 22, 26 | Carl DambkowskiChief Medical Officer | SELL | 26.4K | $132.60 | $3.5M |
| Jun 22, 26 | Michael Thomas HendersonChief Executive Officer | SELL | 80.0K | $132.54 | $10.6M |
| Jun 10, 26 | Michael Thomas HendersonChief Executive Officer | SELL | 7.7K | $86.89 | $634K |
| Jun 3, 26 | Carl DambkowskiChief Medical Officer | SELL | 5.5K | $78.71 | $433K |
| May 13, 26 | Michael Thomas HendersonChief Executive Officer | SELL | 18.7K | $82.58 | $1.5M |
| May 6, 26 | Carl DambkowskiChief Medical Officer | SELL | 3.7K | $84.60 | $311K |
| May 1, 26 | Jane HendersonChief Financial Officer | SELL | 900 | $83.16 | $74K |
| Apr 16, 26 | Jane HendersonChief Financial Officer | SELL | 2.0K | $90.00 | $180K |
| Apr 8, 26 | Michael Thomas HendersonChief Executive Officer | SELL | 17.8K | $85.00 | $1.5M |
| Mar 25, 26 | Jane HendersonChief Financial Officer | SELL | 2.0K | $85.00 | $170K |
| Mar 11, 26 | Michael Thomas HendersonChief Executive Officer | SELL | 8.4K | $75.86 | $621K |
| Mar 4, 26 | Carl DambkowskiChief Medical Officer | SELL | 3.2K | $73.26 | $227K |
| Mar 2, 26 | Jane HendersonChief Financial Officer | SELL | 994 | $71.66 | $70K |
| Feb 11, 26 | Michael Thomas HendersonChief Executive Officer | SELL | 11.5K | $64.99 | $724K |
| Feb 4, 26 | Carl DambkowskiChief Medical Officer | SELL | 2.5K | $68.94 | $161K |
| Feb 2, 26 | Jane HendersonChief Financial Officer | SELL | 1.1K | $66.89 | $73K |
| Jan 22, 26 | Peter Evan HarwinDirector | SELL | 1.75M | $76.30 | $133.5M |
| Jan 14, 26 | Michael Thomas HendersonChief Executive Officer | SELL | 8.5K | $83.79 | $677K |
| Jan 7, 26 | Carl DambkowskiChief Medical Officer | SELL | 14.8K | $80.06 | $1.2M |
| Jan 6, 26 | Jane HendersonChief Financial Officer | SELL | 2.0K | $80.00 | $160K |
| Jan 2, 26 | Jane HendersonChief Financial Officer | SELL | 4.1K | $75.20 | $307K |
| Dec 19, 25 | Jane HendersonChief Financial Officer | SELL | 1.5K | $80.00 | $120K |
| Dec 10, 25 | Michael Thomas HendersonChief Executive Officer | SELL | 10.0K | $76.58 | $758K |
| Dec 4, 25 | Carl DambkowskiChief Medical Officer | SELL | 10.9K | $75.00 | $818K |
| Dec 4, 25 | Michael Thomas HendersonChief Executive Officer | SELL | 40.0K | $75.01 | $3.0M |
| Dec 4, 25 | Jane HendersonChief Financial Officer | SELL | 1.5K | $75.00 | $113K |
| Nov 25, 25 | Jane HendersonChief Financial Officer | SELL | 1.5K | $70.00 | $105K |
| Nov 14, 25 | Jane HendersonChief Financial Officer | SELL | 2.0K | $65.00 | $130K |
| Nov 13, 25 | Michael Thomas HendersonChief Executive Officer | SELL | 14.8K | $64.52 | $933K |
| Nov 11, 25 | Jane HendersonChief Financial Officer | SELL | 1.0K | $60.00 | $60K |
| Nov 5, 25 | Carl DambkowskiChief Medical Officer | SELL | 5.6K | $56.51 | $312K |
| Oct 1, 25 | Carl DambkowskiChief Medical Officer | SELL | 5.1K | $39.80 | $203K |
| Sep 3, 25 | Carl DambkowskiChief Medical Officer | SELL | 2.5K | $38.55 | $96K |
| Aug 6, 25 | Carl DambkowskiChief Medical Officer | SELL | 2.7K | $37.78 | $103K |
| Jul 2, 25 | Carl DambkowskiChief Medical Officer | SELL | 6.4K | $46.26 | $287K |
| Jun 4, 25 | Carl DambkowskiChief Medical Officer | SELL | 2.7K | $36.96 | $101K |
| May 7, 25 | Carl DambkowskiChief Medical Officer | SELL | 2.7K | $35.75 | $97K |
| Apr 2, 25 | Carl DambkowskiChief Medical Officer | SELL | 2.5K | $37.59 | $88K |
| Mar 5, 25 | Carl DambkowskiChief Medical Officer | SELL | 1.6K | $30.48 | $48K |
| Mar 5, 25 | Michael Thomas HendersonChief Executive Officer | SELL | 7.3K | $30.62 | $220K |
| Feb 5, 25 | Carl DambkowskiChief Medical Officer | SELL | 3.5K | $40.69 | $143K |
| Feb 5, 25 | Michael Thomas HendersonChief Executive Officer | SELL | 15.0K | $40.58 | $609K |
| Jan 8, 25 | Michael Thomas HendersonChief Executive Officer | SELL | 12.1K | $49.38 | $591K |
| Jan 2, 25 | Carl DambkowskiChief Medical Officer | SELL | 2.5K | $47.92 | $117K |
| Dec 12, 24 | Mark C. McKennaDirector | BUY | 12.5K | $49.85 | $623K |
| Dec 11, 24 | Carl DambkowskiChief Medical Officer | SELL | 4.1K | $50.00 | $199K |
| Dec 4, 24 | Carl DambkowskiChief Medical Officer | SELL | 6.7K | $46.07 | $307K |
| Dec 4, 24 | Michael Thomas HendersonChief Executive Officer | SELL | 13.3K | $47.19 | $620K |
Over the past 12 months, insiders at Apogee Therapeutics, Inc. filed 0 open-market purchases worth $0 and 79 sales worth $173.0M on APGE, which makes them net sellers over the period. The most recent Form 4 was filed on Jul 8, 26.
The largest recent open-market APGE insider purchase in our data was $623K by Mark C. McKenna, Director, filed on Dec 12, 24.
4 different insiders at Apogee Therapeutics, Inc. filed open-market SEC Form 4 transactions on APGE over the last 12 months.
InsiderTape plots every APGE insider buy and sell directly on the price chart and flags new SEC Form 4 filings as they arrive, with cluster detection and buy/sell pressure. The data updates daily from SEC EDGAR.
InsiderTape plots every Apogee Therapeutics, Inc. insider buy and sell on the price chart, with buy/sell pressure, cluster detection, and alerts the moment new Form 4s hit. Start a free 7-day trial, cancel anytime.
Does it work? In five years of data, insider clusters beat the Russell 2000 about 60% of the time and the CFO's buy was the sharpest signal of all. See the backtest →
START FREE TRIAL →